Transplant for MDS: challenges and emerging strategies

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Allogeneic hematopoietic stem cell transplantation (HSCT) is the sole curative option for myelodysplastic syndrome (MDS).
• Recent advancements have enhanced HSCT tolerability, expanding its application to elderly patients and those with comorbidities.
• Despite progress, significant challenges persist, including treatment-related toxicities, graft-versus-host disease (GvHD), infections, and disease relapse.

Purpose of the Study:

• To review the current landscape of allogeneic HSCT for MDS.
• To highlight improvements in HSCT that allow for broader patient applicability.
• To emphasize the need for personalized transplant strategies to optimize outcomes.

Main Methods:

• Review of current literature on allogeneic HSCT for MDS.
• Analysis of advancements in conditioning regimens and graft sources.
• Discussion of post-transplant complications and management strategies.

Main Results:

• Improved HSCT protocols have increased its feasibility in older patients and those with comorbidities.
• Understanding of MDS biology and prognosis has advanced.
• Various conditioning regimens and graft sources are available.

Conclusions:

• Personalized HSCT strategies, considering individual host factors, are essential for maximizing therapeutic benefits in MDS.
• Careful management of toxicities, GvHD, infections, and relapse is critical for successful transplantation.
• Continued research into disease biology and transplant techniques will further refine treatment approaches for MDS.